

PT/INR MONITORING IS AT HAND

WITH NEW DIRECT CLOT DETECTION TECHNOLOGY



INTRODUCING

Coag-Sense® Prothrombin Time (PT)/INR
Monitoring System

For testing in office or for patient self-testing at home



Coag-Sense PT/INR System Offers Superior



A Breakthrough in PT/INR Testing

- **First system with Direct Clot Detection Technology**
 - Micro-mechanical process offers superb accuracy and precision
 - Not susceptible to changes in Hemoglobin & Hematocrit Levels
 - Ability to run whole blood or plasma samples
- **Barcoding on each test strip**
 - Validates strip outdate—no calibration code input or chip required
- **Internal verification**
 - Performs a system self-check each time a strip is inserted
- **Displays PT results in less than 1 minute**
 - Calculates actual PT time without look-up table or curve-fitting algorithm
 - Allows for immediate patient consultation



Simple, accurate sample collection

- **Requires a small sample size**
 - Just one drop (10 μ L) of blood
- **Uses sample transfer tubes (included)**
 - Allows steady transfer of sample to test strip
 - Reduces strip waste by insuring correct volume delivered
 - Supports blood borne pathogen control efforts



A more direct approach to INR testing

- **Measures actual time required for clotting**
 - The only portable monitoring system that directly detects clotting endpoint—a system that emulates the WHO reference method
- **Allows greater confidence in results**
 - The patented technology of direct clot detection delivers accurate and precise (CV 2.5%) results even in the high INR range (>4.0)
 - Reportable range 0.8–8.0 INR
- **True functional controls included**
 - Two low and high controls using actual thromboplastin reagent and plasma of known INR included with each box of patient test strips.



For *in vitro* diagnostic use

To perform a CLIA-waived test, a certificate of waiver (COW) is required.

Accuracy, Precision & Safety



More frequent testing benefits patients¹

- **Recommendations for improved testing**

- 2008 Joint Commission safety goals call for reduced likelihood of patient harm due to anticoagulation therapy²
- Warfarin black box warning calls for more frequent patient testing³



Extending your control from office to home

- **Consistency of monitoring between your office and patient's home**

- Same system provides consistent results; may help patients become more compliant under your supervision

- **Convenience of portable, stable tabletop design**

- Combined with sample transfer method, helps patients with limited motor skills steadily apply fingerstick sample

- **Independent Diagnostic Testing Facility (IDTF) supervision**

- Coordinates patient's home testing results; reports results to you; can help improve testing adherence, insurance adjudication, and ordering supplies
- Reduces burden on you, freeing you to manage more complex patient cases

- **Reimbursable**

- Medicare covers weekly home PT/INR monitoring for patients with mechanical heart valves, chronic atrial fibrillation, or venous thromboembolism



For *in vitro* diagnostic use

Professional Intended Use: The Coag-Sense Prothrombin Time (PT)/INR Monitoring System is an *in vitro* diagnostic device that provides quantitative prothrombin time (PT) results, expressed in seconds and INR units. It uses fresh capillary whole blood. It is intended for use by health care professionals at the point of care to monitor patients who are on warfarin-type (coumarin) anticoagulation therapy. The device is not intended to be used for screening purposes.



Coag-Sense PT/INR System:

PT/INR MONITORING IS AT HAND



For use in office



Transfer tube stabilizes sample collection



Directly detects clot formation



Improved confidence in INR results



For patient self-testing at home

Ordering Information

06F23-64 COAG-SENSE PROFESSIONAL PT/INR SYSTEM 5-BOX PROMO KIT

03P60-01 COAG-SENSE PROFESSIONAL PT/INR SYSTEM

03P56-50 COAG-SENSE PROFESSIONAL TEST STRIP KIT- 50

References:

1. Oral anticoagulation patient self-testing: Consensus guidelines for practical implementation. *Managed Care*. 2008;17(suppl 9):1-8.
2. 2008 National Patient Safety Goals. The Joint Commission. Available at: www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/08_amb_npsgs.htm. Accessed November 2009.
3. New labeling stresses bleeding risk from Coumadin. U.S. Food and Drug Administration. FDA Patient Safety News Web site. www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=58. Accessed March 25, 2010.

© CoaguSense Inc.
48377 Fremont Blvd., ste 113
Fremont, CA 94538
(510) 270-5442
(510) 226-6540 (Fax)
www.coagusense.com

Coag-Sense is a registered trademark of CoaguSense, Inc.

Cleared for home use	Yes
Cleared for professional use	Yes
Sample size	1 drop (10 µL) capillary blood minimum
Sampling method	21g lancet; sample transfer tube
Device specifications	Portable
Size	3 in (7.6 cm) x 6.5 in (16.5 cm) x 5.75 in (14.5 cm)
Weight	1.2 lb (0.5 kg) with batteries
Test strips packaging	Individually pouched in boxed quantities
Storage	Non-refrigerated, up to 24-month outdate
Tracking	Barcoded
Heparin sensitive	Yes
Clot detection principle	Direct; measures actual time required for clotting
INR range	0.8–8.0
ISI	~1.0
Prothrombin time (PT)	8–80 seconds
Analysis time	<1 minute
QC	External
Memory	100 tests
Barcoded test strips	Yes
Power source	4 AA batteries/AC adapter (professional only)
Warranty	1 year with immediate replacement

For in vitro diagnostic use

Self-Testing Intended Use: The Coag-Sense Self-Test PT Monitoring System is an in vitro diagnostic device that provides quantitative prothrombin time (PT) results, expressed in seconds and international normalized ratio (INR) units. It uses fresh capillary whole blood. It is intended for use by properly selected and suitably trained patients or their caregivers on the order of the treating doctor. Patients should be stabilized on warfarin-type (coumarin) anticoagulation therapy prior to self-testing with the Coag-Sense Self-Test PT Monitoring System. It is not intended to be used for screening purposes.

